Study of BL-M08D1 for returning blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called BL-M08D1 for people with lymphoma or other blood cancers that came back or didn't respond to standard treatments. It aims to see if the drug can help when other options are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old
- Your lymphoma or blood cancer has come back or not responded to at least one prior treatment and no standard treatment is available
- You must be willing to provide a tumor sample from past biopsy or a new one if possible
- You must have good organ function, including heart, liver, kidneys, and blood clotting
- You cannot have serious heart disease, uncontrolled high blood pressure, diabetes complications, or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
This study tests an experimental drug called BL-M08D1 for people with head and neck cancer that has returned or spread. The drug is designed to target and destroy cancer cells, and the study will check if it is safe and how well it works.
This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called BL-M08D for people with advanced digestive tract tumors or other solid tumors that have spread. It aims to see if the drug can shrink tumors and improve survival, while monitoring safety.
This study tests a new drug called BL-M05D1 for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Hear when a new Relapsed or Refractory Lymphoid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.